Roche’s lung cancer drug combo study shows improvement in progression-free survival

This article was originally published here

PBR Staff Writer Published 08 December 2017

Roche has announced that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) has extended the life of patients with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC) in the Phase III IMpower150 study.

The study demonstrated that the Tecentriq combination has more effectively reduced the disease progression in patients compared to those who received Avastin plus chemotherapy.

IMpower150 is a multicenter, open-label, randomized and controlled study designed to assess the efficacy and safety of Tecentriq in combination with chemotherapy with or without Avastin in people with stage IV or recurrent metastatic non-squamous NSCLC.

The company had recruited 1,202 patients, of which those with ALK and EGFR mutations were excluded from the primary ITT analysis.

The patients have been randomized in 1:1:1 ratio to secure Tecentriq plus carboplatin and paclitaxel, Tecentriq and Avastin plus carboplatin and paclitaxel and Avastin plus carboplatin and paclitaxel.

According to the company, the co-primary endpoints were progression-free survival and overall survival, which were determined by the investigator.

Roche chief medical officer and global product development head Dr Sandra Horning said: “This Tecentriq study is the first positive Phase III combination trial that showed a cancer immunotherapy reduced the risk of the disease getting worse when used as an initial treatment in a broad group of people with advanced non-squamous NSCLC.

“The IMpower150 study represents an important advance in lung cancer treatment, and we will submit these results to regulatory authorities around the world to potentially bring a new standard of care to people living with this disease as soon as possible.”

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply